When this gene is mutated in LAM patients, it loses its regulatory function of the TSC gene, leading to overactivation of the mammalian target of rapamycin (mTOR) (13), a key regulator of cell growth and proliferation (14). Here, MTOR is linked to lymphangioleiomyomatosis.